Stockreport

Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

Bicara Therapeutics Inc.  (BCAX) 
PDF Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substant [Read more]